GTx GTXI

  1. All
  2. Commentary
  3. Headlines

    Related Topics:

    1. How’s the Market Feeling These Days?

      Headlines

      Thu, 16 Oct 2014

      GTx GTXI announced Thursday that the Data Safety Monitoring Board has ..... drug's composition of matter patent may expire around the time GTx expects an FDA approval in 2009. After that, GTx may need to rely on weak patents for market exclusivity.

    2. When Flexibility Meets Opportunity in the European Commercial Real Estate Market

      Headlines

      Wed, 13 Nov 2013

      We are raising GTx 's fair value on recent positive Phase II trial results for Ostarine.

    3. America: The New Europe?

      Headlines

      Wed, 2 Oct 2013

      GTx adds a European partner.

    4. GTx muscle drug fails late-stage trials, shares plunge

      Headlines

      Mon, 19 Aug 2013

      (Reuters) - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value...

    5. Dropping Coverage of GTx

      Commentary

      Sun, 24 Oct 2010

      We're dropping coverage of GTx Inc GTXI to focus our resources elsewhere.

    6. Drug Development Moves Along at GTx

      Commentary

      Fri, 17 Sep 2010

      GTx Inc. GTXI reported second-quarter results that came ..... treatment for advanced prostate cancer, GTx -758, met endpoints in a Phase II study ..... Administration, and will continue to push ahead on GTx 758. In the meantime, GTx continues to

    7. Disappointing Results for GTx

      Commentary

      Wed, 26 May 2010

      GTx GTXI reported disappointing results in its Phase III trial for Acapodene for the ..... study protocol and demands a larger or more expensive trial that rises above GTx and partner Ipsen's preset funding threshold for a second trial . Then the

    8. GTx , Ipsen Expand Deal

      Commentary

      Tue, 23 Mar 2010

      GTx GTXI announced Tuesday that it has expanded its deal with European partner Ipsen . Ipsen will pay GTx about $ 58 million in milestones for a second ..... European approval . This deal will improve GTx 's near - term cash reserves and help it

    9. GTx under Review

      Commentary

      Wed, 3 Mar 2010

      We are placing GTx GTXI under review until the firm reports earnings ..... of the Ostarine (MK-2866) compound. GTx partnered with Merck MRK on this compound ..... currently discussing next steps with GTx ." Ostarine drives the lion's share

    10. GTx 4Q Preview

      Commentary

      Tue, 23 Feb 2010

      GTx GTXI will report fourth-quarter results soon ..... Administration's complete response letter in November, GTx stated it planned to meet with the agency ..... scenario. We are also interested in whether GTx can use data from its prostate cancer prevention

    « Prev123Next »
    Content Partners